NY-ESO-1表达预测卵巢癌侵袭性表型
本研究在1002例卵巢癌(含输卵管癌和原发性腹膜癌)患者中检测NY-ESO-1表达,发现40.7%肿瘤表达NY-ESO-1,且表达者分期更高、完全缓解率更低、总生存更短;接受靶向该抗原免疫治疗的NY-ESO-1+患者总生存改善超过2年。
要点
- NY-ESO-1在40.7%的卵巢癌肿瘤中表达,689例可测患者中19.0%存在基线体液免疫应答。
- NY-ESO-1+患者分期更高(III/IV期85% vs 76.4%)、完全缓解率更低(53.9% vs 68.9%)、总生存更短(42.9 vs 50.0个月)。
- NY-ESO-1+患者接受靶向该抗原的免疫治疗后总生存改善超过2年(52.6 vs 27.2个月)。
核心结论
- 本研究首次证明NY-ESO-1表达与卵巢癌侵袭性表型相关。
- NY-ESO-1在卵巢癌中表达频率较高且NY-ESO-1+患者临床结局较差,揭示针对该抗原的靶向治疗存在未被充分认识的需求。
- NY-ESO-1+患者入组靶向该抗原的免疫治疗试验后总生存改善。
研究设计与样本
- 研究采用免疫组织化学(IHC)、逆转录聚合酶链反应(RT-PCR)和定量PCR(qRT-PCR)在卵巢癌(包括输卵管癌和原发性腹膜癌)患者队列中检测NY-ESO-1表达。
- 采用酶联免疫吸附试验(ELISA)测定针对NY-ESO-1的体液免疫应答。
- 基于NY-ESO-1表达评估无进展生存(PFS)和总生存(OS)等临床病理结局,并用Cohen κ检验表达检测方法间的一致性。
主要发现
- 任何方法检测到NY-ESO-1表达的肿瘤占1002例患者的40.7%(NY-ESO-1+),689例受检患者中19.0%存在基线体液免疫应答。
- NY-ESO-1+患者年龄更大(p<0.001),分期更高(III/IV期85% vs 76.4%,p=0.015),对初始治疗获得完全缓解的可能性更低(53.9% vs 68.9%,p=0.002),浆液性组织型更多(74.5% vs 66.9%,p=0.011),3级肿瘤更多(83.7% vs 70.8%,p<0.001)。
- NY-ESO-1+患者无进展生存有缩短趋势(22.2 vs 25.0个月,p=0.07),总生存显著更短(42.9 vs 50.0个月,p=0.003)。
- 接受免疫治疗的NY-ESO-1+患者亚组分析显示总生存改善超过2年(52.6 vs 27.2个月,p<0.001)。
关键数值与推荐
- NY-ESO-1表达频率为40.7%(1002例患者),基线体液免疫应答为19.0%(689例受检患者)。
- NY-ESO-1+患者完全缓解率为53.9%,NY-ESO-1-患者为68.9%(p=0.002)。
- NY-ESO-1+患者总生存为42.9个月,NY-ESO-1-患者为50.0个月(p=0.003)。
- 接受免疫治疗的NY-ESO-1+患者总生存为52.6个月,未接受者为27.2个月(p<0.001)。
临床怎么用
- 作者认为NY-ESO-1在卵巢癌中表达频率较高且NY-ESO-1+患者临床结局较差,揭示针对该抗原的靶向治疗存在未被充分认识的需求。
- 作者报告NY-ESO-1+患者入组靶向该抗原的免疫治疗试验后总生存改善。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: NY-ESO-1 is a cancer testis antigen and a promising target for immunotherapy. The purpose of this study was to determine the expression frequency, immunogenicity, and clinical impact of NY-ESO-1 in ovarian cancer. METHODS: Immunohistochemistry (IHC), reverse-transcription polymerase chain reaction (RT-PCR), and quantitative-PCR (qRT-PCR) were utilized in an ovarian cancer (including Fallopian tube and primary peritoneal cancers) patient cohort; humoral responses against NY-ESO-1 were determined by ELISA. Clinicopathologic outcomes including progression-free (PFS) and overall (OS) survival were evaluated based on NY-ESO-1 expression. Cohen's kappa (κ) tested agreement between expression tests. RESULTS: NY-ESO-1 expression was detected by any method in 40.7% of 1002 patients' tumors (NY-ESO-1+) and baseline humoral response was identified in 19.0% of 689 tested patients. NY-ESO-1+ patients were older (p<0.001), higher stage (85% stage III/IV vs. 76.4%, p=0.015), less likely to have a complete response to initial therapy (53.9% vs. 68.9%, p=0.002), had more serous histotype (74.5% vs. 66.9%, p=0.011), and had more grade 3 tumors (83.7% vs. 70.8%, p<0.001). There was a trend towards shorter PFS (22.2 vs. 25.0months, p=0.07) and significantly shorter OS (42.9 vs. 50.0months, p=0.003) among NY-ESO-1+ patients. A subset analysis of NY-ESO-1+ patients that received immunotherapy demonstrated improved OS by >2years (52.6 vs. 27.2months, p<0.001). CONCLUSIONS: This study is the first demonstration of an association between NY-ESO-1 expression and an aggressive cancer phenotype. The relatively high expression frequency of NY-ESO-1 in ovarian cancer patients coupled with the poor clinical outcomes in NY-ESO-1+ patients reveals an underappreciated need for targeted therapy against this antigen. In support, our study reveals that NY-ESO-1+ patients enrolled on immunotherapy trials targeting the antigen exhibited an improvement in OS.
引用
- Szender JB, Papanicolau-Sengos A, Eng KH, et al. NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol. 2017. PMID: 28392127. doi:10.1016/j.ygyno.2017.03.509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。